BR112013020719A2 - composições de derivados de bimatoprost tipo éster e métodos - Google Patents

composições de derivados de bimatoprost tipo éster e métodos

Info

Publication number
BR112013020719A2
BR112013020719A2 BR112013020719A BR112013020719A BR112013020719A2 BR 112013020719 A2 BR112013020719 A2 BR 112013020719A2 BR 112013020719 A BR112013020719 A BR 112013020719A BR 112013020719 A BR112013020719 A BR 112013020719A BR 112013020719 A2 BR112013020719 A2 BR 112013020719A2
Authority
BR
Brazil
Prior art keywords
methods
bimatoprost
ester
type
derivative compositions
Prior art date
Application number
BR112013020719A
Other languages
English (en)
Other versions
BR112013020719B1 (pt
Inventor
David F Wooward
Jenny W Wang
Michael E Garst
Neil J Poloso
Robert M Burk
Todd S Gac
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013020719A2 publication Critical patent/BR112013020719A2/pt
Publication of BR112013020719B1 publication Critical patent/BR112013020719B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições de derivados de bimatoprost tipo éster e métodos a presente invenção oferece, inter alia, pró-drogas de bimatoprost, métodos de uso das mesmas e composições incluindo as mesmas.
BR112013020719-1A 2011-02-14 2012-02-13 Composições de derivados de bimatoprost tipo éster e métodos BR112013020719B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442400P 2011-02-14 2011-02-14
US61/442,400 2011-02-14
PCT/US2012/024881 WO2012112451A1 (en) 2011-02-14 2012-02-13 Ester derivatives of bimatoprost compositions and methods

Publications (2)

Publication Number Publication Date
BR112013020719A2 true BR112013020719A2 (pt) 2016-08-09
BR112013020719B1 BR112013020719B1 (pt) 2018-04-17

Family

ID=45755562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020719-1A BR112013020719B1 (pt) 2011-02-14 2012-02-13 Composições de derivados de bimatoprost tipo éster e métodos

Country Status (12)

Country Link
US (3) US8865766B2 (pt)
EP (1) EP2675786B1 (pt)
JP (1) JP5885271B2 (pt)
KR (1) KR101935068B1 (pt)
CN (1) CN103459368B (pt)
AR (1) AR088774A1 (pt)
AU (1) AU2012217922B2 (pt)
BR (1) BR112013020719B1 (pt)
CA (1) CA2827446C (pt)
RU (1) RU2599249C2 (pt)
TW (1) TWI642653B (pt)
WO (1) WO2012112451A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20120322882A1 (en) 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth
ES2579990T3 (es) 2011-01-19 2016-08-18 Terakine Therapeutics, Inc. Métodos y composiciones para tratar el síndrome metabólico
US8859616B2 (en) * 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2014070784A1 (en) * 2012-10-29 2014-05-08 Allergan, Inc. Phosphate esters of bimatoprost and the prostamides
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
CN109106606A (zh) * 2013-03-14 2019-01-01 阿勒根公司 包含比马前列素的局部组合物和利用其刺激毛发生长的方法
NO2753788T3 (pt) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
JP2818381B2 (ja) * 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
CA2602440A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US8252771B2 (en) * 2007-01-31 2012-08-28 Allergan, Inc. Biomaterials and a method for making and using same
MX2010004834A (es) * 2007-10-31 2010-10-20 Pamela Lipkin Composiciones de analogos de prostaglandina y metodos para tratar las condiciones relacionadas al epitelio.
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US20120322882A1 (en) 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth

Also Published As

Publication number Publication date
KR20140015364A (ko) 2014-02-06
US8865766B2 (en) 2014-10-21
EP2675786A1 (en) 2013-12-25
BR112013020719B1 (pt) 2018-04-17
TW201247613A (en) 2012-12-01
US20150005377A1 (en) 2015-01-01
CN103459368A (zh) 2013-12-18
CN103459368B (zh) 2016-06-08
JP2014513051A (ja) 2014-05-29
US9499478B2 (en) 2016-11-22
AU2012217922B2 (en) 2017-05-04
US20120295972A1 (en) 2012-11-22
KR101935068B1 (ko) 2019-01-03
WO2012112451A1 (en) 2012-08-23
CA2827446C (en) 2020-06-23
EP2675786B1 (en) 2018-12-26
AR088774A1 (es) 2014-07-10
TWI642653B (zh) 2018-12-01
JP5885271B2 (ja) 2016-03-15
AU2012217922A1 (en) 2013-09-05
RU2599249C2 (ru) 2016-10-10
US20130324606A1 (en) 2013-12-05
RU2013141849A (ru) 2015-03-27
CA2827446A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
BR112013020719A2 (pt) composições de derivados de bimatoprost tipo éster e métodos
IN2014CN02639A (pt)
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
BR112013017183A2 (pt) composições de bepostatina
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
DK2931970T4 (da) Cellulose-afledte sammensætninger
BR112014023200A2 (pt) uso de uma composição
UY34365A (es) Compuestos heterociclicos
SMT201700110B (it) Composizione immunogena
CO6930368A2 (es) Composiciones de yodo-povidona estable
UY33906A (es) Composiciones herbicidas que comprenden topramezona
DK2882433T3 (da) Antimikrobielle sammensætninger omfattende glycerylnitrater
UY34119A (es) Montaje machihembrado de fijación
TR201909271T4 (tr) Testosteron formülasyonları.
BR112014003027A2 (pt) formulação herbicida melhorada
BR112013025866A2 (pt) formulações com viscosidade reduzida
UY34442A (es) 2-tiopirimidinonas.
BR112013014612A2 (pt) composições moc
UY34158A (es) Composicion herbicida
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
UY33864A (es) Novedoso Derivado Cristalino de Oxazina
BR112014029156A2 (pt) arma curta curvada
UY34783A (es) Segadora
UY34286A (es) Diagnóstico de vacuna mejorado
BR112013031545A2 (pt) composições cosméticas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2761 DE 05-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.